A recent study has unveiled a comprehensive mapping of the cereblon (CRBN) interactome, revealing over 200 potential drug targets for molecular glue degraders (MGDs). These findings could significantly enhance the development of targeted therapies for diseases like multiple myeloma.
Understanding CRBN and MGDs
Molecular glue degraders, such as pomalidomide, facilitate the degradation of non-native substrates via the cullin-RING E3 ligase 4 (CRL4) through its substrate receptor cereblon (CRBN). This study aimed to explore the programmability of CRBN by investigating whether known CRBN–MGD substrates are part of a broader network of latent interactors capable of binding to CRBN without leading to detectable degradation.
Innovative Methodology
The researchers employed a highly parallel protein complementation assay known as GluePCA to measure MGD-induced interactions between CRBN and various zinc finger proteins. This approach identified approximately 210 zinc fingers that bound to CRBN in the presence of pomalidomide, with several of the top binders already recognized as degraded by specific MGDs.
To map the CRBN–MGD interactions across the proteome, the team combined GluePCA with artificial intelligence-derived protein surface queries, referred to as MaSIF-mimicry. This integrated pipeline identified 6 known and 43 novel CRBN–pomalidomide binders, including hits that were validated through orthogonal methods.
Key Findings and Implications
The results indicate that these identified binders serve as valuable starting points for the development of new MGDs. The study highlights the potential of this binding-focused workflow to be applied to other MGD–E3 ligase systems, thereby broadening the therapeutic landscape of this emerging drug class.
Historically, the discovery of MGDs has relied on phenotypic screening of extensive chemical libraries. However, this study presents a scalable workflow that comprehensively maps the CRBN–MGD interaction space, overcoming the limitations of traditional biochemical methods.
Conclusion
By identifying a wide array of potential CRBN interactors, this research paves the way for more targeted and effective therapeutic strategies. The findings underscore the importance of understanding protein interactions in the context of drug development, particularly for diseases with limited treatment options.
This article was produced by NeonPulse.today using human and AI-assisted editorial processes, based on publicly available information. Content may be edited for clarity and style.
